These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1287 related items for PubMed ID: 22508468

  • 21. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
    Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK.
    Arthritis Rheum; 2002 Jun; 46(6):1443-50. PubMed ID: 12115173
    [Abstract] [Full Text] [Related]

  • 22. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
    Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Wallman JK, Ernestam S, Bolce RJ, van Vollenhoven RF.
    Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.
    Pope JE, Haraoui B, Thorne JC, Vieira A, Poulin-Costello M, Keystone EC.
    Ann Rheum Dis; 2014 Dec; 73(12):2144-51. PubMed ID: 23979914
    [Abstract] [Full Text] [Related]

  • 25. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K, Akkoç N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, Rahman MU, Pedersen R, Dinh A, Shen Q, Vasilescu R, Kotak S, Mahgoub E, Vlahos B.
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [Abstract] [Full Text] [Related]

  • 26. Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis.
    Bhavsar SV, Movahedi M, Cesta A, Pope JE, Bombardier C, other OBRI investigators.
    Joint Bone Spine; 2024 Jul; 91(4):105732. PubMed ID: 38583692
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.
    van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, Freundlich B, MacPeek D, Add Enbrel or Replace Methotrexate Study Investigators.
    Ann Rheum Dis; 2006 Nov; 65(11):1478-83. PubMed ID: 16464988
    [Abstract] [Full Text] [Related]

  • 28. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.
    Wakabayashi H, Hasegawa M, Nishioka Y, Minami Y, Nishioka K, Sudo A.
    Clin Rheumatol; 2013 Feb; 32(2):253-9. PubMed ID: 23179002
    [Abstract] [Full Text] [Related]

  • 29. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial.
    Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, Gough A, Quinn M, Reece R, Cox SR, Buch MH, van der Heijde DM, Emery P.
    Ann Rheum Dis; 2014 Jun; 73(6):1027-36. PubMed ID: 24618266
    [Abstract] [Full Text] [Related]

  • 30. Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study.
    Emery P, Kvien TK, Combe B, Freundlich B, Robertson D, Ferdousi T, Bananis E, Pedersen R, Koenig AS.
    Ann Rheum Dis; 2012 Jun; 71(6):989-92. PubMed ID: 22402142
    [Abstract] [Full Text] [Related]

  • 31. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G.
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study.
    Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, Takeuchi T.
    J Rheumatol; 2011 Aug; 38(8):1585-92. PubMed ID: 21572151
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Krüger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Höhne-Zimmer V, Egerer K, Buttgereit F, Burmester GR.
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [Abstract] [Full Text] [Related]

  • 38. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE, Bochkova AG, Bunchuk NV.
    Ter Arkh; 2008 Jun; 80(5):25-30. PubMed ID: 18590110
    [Abstract] [Full Text] [Related]

  • 39. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA, Guzman RM, Xavier RM, Simon JA, Mele L, Pedersen R, Ferdousi T, Koenig AS, Kotak S, Vlahos B.
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [Abstract] [Full Text] [Related]

  • 40. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM.
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 65.